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Abstract
Background
To enhance risk stratification for Wilms tumour (WT) in a pre-operative chemotherapy set-
ting, we explored the prognostic significance and optimal age cutoffs in patients treated
according to International Society of Paediatric Oncology Renal Tumour Study Group
(SIOP-RTSG) protocols.
Methods
Patients(6 months-18 years) with unilateral WT were selected from prospective SIOP 93–
01 and 2001 studies(1993–2016). Martingale residual analysis was used to explore optimal
age cutoffs. Outcome according to age was analyzed by uni- and multivariable analysis,
adjusted for sex, biopsy(yes/no), stage, histology and tumour volume at surgery.
Results
5631 patients were included; median age was 3.4 years(IQR: 2–5.1). Estimated 5-year
event-free survival (EFS) and overall survival (OS) were 85%(95%CI 83.5–85.5) and 93%
(95%CI 92.0–93.4). Martingale residual plots detected no optimal age cutoffs. Multivariable
analysis showed lower EFS with increasing age(linear trend P<0.001). Using previously
described age categories, EFS was lower for patients aged 2-4(HR 1.34, P = 0.02), 4-10
(HR 1.83, P<0.0001) and 10–18 years(HR 1.74, P = 0.01) as compared to patients aged 6
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months-2 years. OS was lower for patients 4–10 years(HR 1.67, P = 0.01) and 10–18 years
(HR 1.87, P = 0.04), but not for 2–4 years(HR 1.29, P = 0.23). Higher stage, histological risk
group and tumour volume were independent adverse prognostic factors.
Conclusion
Although optimal age cutoffs could not be identified, we demonstrated the prognostic signifi-
cance of age as well as previously described cutoffs for EFS (2 and 4 years) and OS (4
years) in children with WT treated with pre-operative chemotherapy. These findings encour-
age the consideration of age in the design of future SIOP-RTSG protocols.
Introduction
As treatment for Wilms tumour (WT) is evolving towards further risk adaptation, there is an
increasing interest in additional factors that can help to stratify treatment intensity based on
the patient’s individual risk. One of these factors appears to be a patient’s age at diagnosis.
Older age has been suggested to be an adverse prognostic factor for recurrence and mortality
[1–4] while younger patients may need less intensive treatment.[5–8]
Treatment stratification of WT has been primarily based on pathological stage and histol-
ogy. More recently, potential molecular prognostic markers such as copy number changes and
loss of heterozygosity (LOH) of specific chromosomal regions are emerging.[9–15] Currently,
in addition to tumour weight, LOH 1p/16q, stage and histology, the Children’s Oncology
Group (COG) includes age in the risk stratification of its most recent protocols.[5, 7] So far,
the independent prognostic significance of age has not been sufficiently validated in a large
cohort of patients treated with pre-operative chemotherapy, as recommended in International
Society of Paediatric Oncology Renal Tumour Study Group (SIOP-RTSG) protocols (S1
Table).
Age as a prognostic factor was first described in 1976 when D’Angio et al.[1] reported that
the addition of postoperative radiation therapy did not improve the already excellent outcomes
of patients <2 years with stage I disease, treated with primary surgery in National Wilms
tumour Study (NWTS)-1.[1] After a pooled analysis of NWTS-1, -2 and -3, the ‘very low risk’
patients <2 years with stage I, non-anaplastic WT(lymph node sampling required), tumour
weight <550 grams, without predisposition syndromes, were subsequently treated with
nephrectomy only, in Children’s Oncology Group (COG) protocols.[5–8]
Whether the age of 2 years is the optimal cutoff for risk stratification was debated in a later
study by the UK Children’s Cancer Study Group, suggesting that the age of 4 years may be a
more relevant cutoff in the setting of minimal adjuvant chemotherapy.[3] The Associazione
Italiana Ematologia Oncologia Pediatrica (AIEOP) study that used a cutoff at the age of 2
years, did not find older age to be an independent prognostic factor in stage I-IV WT.[16] By
contrast, the relatively small subgroup of WT patients older than 10 years, revealed a particu-
larly poor survival(63–70%) in reports from the Automated Childhood Cancer Information
System (ACCIS) and UK Children’s Cancer And Leukemia Group, compared to a survival of
80–90% in younger patients.[17, 18]
In the current study, we aimed to assess the prognostic significance of age in a large, pro-
spectively registered cohort of paediatric patients with WT treated with pre-operative chemo-
therapy according to recent SIOP protocols. Moreover, we aimed to identify relevant age
cutoffs for future stratification purposes.
Prognostic significance of age in patients with Wilms tumour
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Patients and methods
Patients
Patients with histologically proven stage I-IV WT, aged 6 months-18 years, treated according
to SIOP 93–01[19] and SIOP 2001[20] protocols (including the SIOP WT 2001 trial with
EudraCT number 2007-004591-39) from 1993–2016 and prospectively registered in the SIOP
database, were included in this retrospective analysis. The SIOP-RTSG steering committee
approved the research proposal for this specific study and anonymized data were made avail-
able to the researchers through statistical reports generated by data scientists of the SIOP-
RTSG office. Patients <6 months were excluded as they received separate treatment regimen.
[21] Moreover, patients with bilateral disease, non-Wilms tumours or extrarenal tumour sites
were excluded. Subsets of patients from the SIOP database had been previously described in
several reports.[9, 18–20, 22, 23] For both protocols ethical approval was obtained by ethical
committees of all participating countries, and written informed consent for participation was
obtained from the parents or legal representatives of the patients.
SIOP 93–01 and SIOP 2001 protocols
Pre-operative chemotherapy consisted of 4 weeks of vincristine and actinomycin-D in case of
localized disease, and 6 weeks of vincristine, actinomycin-D and doxorubicin in case of meta-
static disease. Biopsy before start of treatment was not recommended as a standard procedure,
but was allowed without upstaging if performed by a percutaneous fine needle or trucut proce-
dure. This was a routine procedure in the Children’s Cancer and Leukemia Group (CCLG),
including the UK and Republic of Ireland, that participated in SIOP 2001 but not SIOP 93–01.
Post-operative treatment stratification depended on SIOP stage and histological risk group
[24, 25], and evolved over time. In SIOP 93–01, post-operative chemotherapy was randomized
for stage I intermediate-risk and anaplastic WT, with the trial arm receiving a shorter treat-
ment regimen, which was subsequently adopted for intermediate-risk WT in SIOP 2001.[19]
Non-viable tumour tissue in the renal sinus and perirenal fat was no longer taken into account
for upstaging histological risk group in SIOP 2001. Moreover, focal anaplasia (which was con-
sidered high-risk in SIOP 93–01) was considered intermediate risk and treated accordingly;
while blastemal-type WT was considered high-risk and treated accordingly.[23, 24] For stage
II-III intermediate risk tumours, the SIOP 2001 randomized trial provided evidence for omit-
ting doxorubicin, and this was adjusted accordingly from 2011 onwards in the continuation of
the SIOP 2001 protocol.[20]
In the current analysis, high-risk tumours included diffuse anaplastic and/or blastemal-type
WT after pre-operative chemotherapy. Intermediate risk tumours were either stromal, epithe-
lial, mixed or regressive type or focal anaplasia, while low risk was defined as completely
necrotic tumours after pre-operative chemotherapy. Central pathology review was performed
for 83.4% of patients in SIOP 2001, and for 94.4% of patients in SIOP 93–01. Tumour volume
was not a factor for treatment stratification, with the exception of German Paediatric Oncol-
ogy Haematology (GPOH) centers, where patients with non-stromal, non-epithelial interme-
diate risk WT and a tumour volume >500mL at surgery, received ‘high-risk’ post-operative
chemotherapy (four drugs).[26]
Statistical methods
To search for potential relevant prognostic age cutoffs in relation to event-free survival (EFS)
and overall survival (OS), martingale residual plots were evaluated.[27] Cox regression models
were used to analyze the prognostic significance of age. Variables assessed in univariable
Prognostic significance of age in patients with Wilms tumour
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analysis were age, sex, biopsy (yes/no), overall stage, histological classification and tumour vol-
ume at surgery(radiologically assessed, dichotomized as�500 ml and>500 ml). Variables that
appeared to be associated with EFS/OS in univariable analysis (P<0.10) and/or were known
confounders based on previous literature, were entered into the multivariable model, stratified
by national/regional group and study protocol (SIOP 2001 and SIOP 93–01). Patient charac-
teristics were compared using Pearson’s Chi-Squared test for categorical variables, and Mann
Whitney’s U-test/Kruskall-Wallis for continuous variables.
Tumour volume at surgery was missing in 18�3% of cases, and was imputed using multiple
imputation techniques (fully conditional method) on 100 generated datasets, assuming it was
missing at random. Missing volume was associated with center/consortium and not with
patient characteristics, and there were no indications that it might be related to unobserved
characteristics or the missing volume itself. Resulting model estimates were combined using
SAS PROC MIANALYZE software (version 9.4).
Results
Patient characteristics
Out of 7262 registered patients with histologically proven WT, 5631 met the inclusion criteria
(78%) (S1 Fig). Baseline characteristics are summarized in Table 1. Median follow-up at time
of data capture was 6�3 years (interquartile range, IQR: 3�0–8�7). Median age at diagnosis was
3�4 years (IQR: 2–5�1) with only 189 patients (3�4%) aged 10 years or older. Median age was
3�6 (IQR 2–5�2) for females and 3�2 (IQR 1�9–4�9) for males (P<0.001). The age distribution
of females showed two peaks, at around 1 year and 4 years. For males there was an early peak
in the age distribution but bimodality was less apparent than for females (Fig 1). Forty-five
percent (N = 2554) presented with overall stage I disease, 23% (N = 1271) with stage II, 17%
(N = 949) with stage III and 15% (N = 857) with stage IV. WT’s were histologically classified as
low-risk in 5�6% (N = 315), intermediate risk in 82% (N = 4566), high-risk blastemal type in
8�3% (N = 466) and high-risk diffuse anaplastic in 4�9% (N = 278). Biopsies were performed in
208 cases (10�5%) in SIOP 93–01 and 1159 cases (31�7%) in SIOP 2001. Tumour volume at sur-
gery was available for 4599 patients (81.7%), of whom 14�1% (N = 649) had a tumour volume
of>500ml at surgery.
Comparison of patient characteristics between age groups
The distribution of stage, histological risk and tumour volume differed between age groups,
with the frequency of metastatic disease, high-risk histology types (most markedly for diffuse
anaplastic WT) and high-volume tumours increasing with age (Table 2).
Optimal age cutoffs
Martingale residual plots (Fig 2) suggested that an increase in age was linearly associated with
the risk of an event. However, since no specific change point (knot) could be clearly observed,
hence, no optimal cutoffs for categorizing age could be identified. Therefore, in further analy-
ses, age was included as a linear factor (per year), as well as categorized according to previous
studies at the ages of 2, 4 and 10 years.
Survival and univariable analysis of prognostic factors
5585 patients were included in the survival analysis, after censoring 46 patients without avail-
able follow-up data. Estimated 5-year EFS and OS of the total cohort was 85% (95% CI 83�5–
85�5) and 93% (95% CI 92�0–93�4) respectively. A total of 836 events occurred, of which 93.8%
Prognostic significance of age in patients with Wilms tumour
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(N = 784) were relapses. In univariable analysis, significant differences in EFS and OS were
found between age categories 6 months– 2 years, 2–4, 4–10 and�10 years (Fig 3). The 5-year
EFS was 91�2% (95% CI 89�7–92�8) for ages 6 months-2 years, 86�3% (95% CI 84�7–87�9) for
2–4 years, 79�3% (95% CI 77�5–81�1) for 4–10 years and 73�5% (95% CI 66�8–80�9) for 10–18
years (log rank P<0�0001). OS was 96�8% (95% CI 95�9–97�8) for ages 6 months-2 years,
94�1% (95% CI 92�9–95�2) for 2–4 years, 89�5% 95% CI 88�1–90�9) for 4–10 years and 84�6%
(95% CI 79�0–90�7) for 10–18 years (P<0�0001).
Multivariable analysis of prognostic factors for EFS
Age categorized as 6 months– 2 years, 2–4 years, 4–10 years and 10–18 years, was a significant
prognostic factor for EFS in multivariable analysis (2–4 years: adjusted HR 1�34, P = 0�02,
4–10 years: adjusted HR 1�83, P<0�0001, 10–18 years: adjusted HR 1�74, P = 0�01), after
Table 1. Baseline patient and disease characteristics (N = 5631).
TOTAL
N %
Protocol SIOP 93–01 1980 35�2
SIOP 2001 3651 64�8
Sex Female 3023 53�7
Male 2608 46�3
Missing 0 0
Age 6 mths– 2 yrs 1439 25�6
2–4 yrs 1939 34�4
4–10 yrs 2064 36�7
10–18 yrs 189 3�4
Missing 0 0
Histology Low risk 315 5�6
Intermediate risk 4566 81�1
High risk–blastemal type 466 8�3
High risk–diffuse anaplastic 278 4�9
Missing 6 0�1
SIOP overall stage I 2554 45�5
II 1271 22�6
III 949 16�9
IV 857 15�2
Missing 0 0
SIOP abdominal stage I 2766 49�3
II 1491 26�6
III 1354 24�1
Missing 4 0�1
Side Left 2880 51�2
Right 2749 48�8
Missing 2 0�03
Biopsy Yes 1367 24�3
No 4264 75�7
Missing 0 0
Volume at surgery �500 ml 3950 70�1
>500 ml 649 11�5
Missing 1032 18�3
https://doi.org/10.1371/journal.pone.0221373.t001
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Fig 1. Distribution of age at diagnosis (smoothed kernel density), displayed for females (top) and males
(bottom). Median age was 3�6 years (IQR 2–5�2) for females and 3�2 years (IQR 1�9–4�9) for males (P<0.001).
https://doi.org/10.1371/journal.pone.0221373.g001
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stratifying for national/regional study group and study protocol, and including sex, overall
stage, histological risk group, biopsy and tumour volume at surgery. Other independent prog-
nostic factors for EFS were overall stage III and IV, histological subtype (low, intermediate or
high-risk) and tumour volume at surgery (Table 3).When replacing the age categories by age
per year in the multivariable model, the linear trend observed in the Martingale residual plot
was confirmed for EFS (adjusted HR 1�06, P<0�0001). The same conclusions were obtained
when imputing missing volume (S2 Table), and when limiting the analysis to SIOP 2001
patients only (N = 3132, S3 Table).
Multivariable analysis of prognostic factors for OS
For OS, the age category 2–4 years (adjusted HR 1�23, P = 0�29) did not retain significance in
multivariable analysis. However, patients aged 4–10 (adjusted HR 1�67, P = 0�01) and 10–18
years (adjusted HR 1�87, P = 0�04) revealed lower OS compared to patients aged 6 months– 2
years. Other factors that were significantly associated with OS included overall stage III and
IV, histological classification and tumour volume at surgery (Table 4). When including age as
a continuous variable in the multivariable model, this did not reach statistical significance
(adjusted HR 1�04, P = 0�06). These conclusions were maintained when imputing missing vol-
ume (S4 Table). When limiting the analysis to SIOP 2001 patients, age (categorized or contin-
uous) did not retain significance (N = 3132, S5 Table).
Discussion
This study, which included 5631 patients with unilateral WT registered over 23 years in the
recent SIOP trials, demonstrated that age is an independent prognostic factor for EFS in
patients treated with pre-operative chemotherapy. Although optimal age cutoffs for risk strati-
fication could not be identified, the prognostic significance of previously described cutoffs was
confirmed for EFS (2 and 4 years) and OS (4 years). Despite the observation that older patients
more frequently have a higher stage at diagnosis, high-risk histology types and large-volume
tumours, age retained independent prognostic significance. Interestingly, the strong prognos-
tic value of tumour volume�500mL confirmed previous findings from the posthoc analysis of
the SIOP 2001 randomized trial.[20, 26] While previous studies have reported conflicting
results on the prognostic value of age, depending on sample size and whether age was included
as a categorized or continuous variable, our findings are in line with the results described in
other large cohorts (>1000 patients, S1 Table).
Table 2. Comparison of patient characteristics between age groups (SIOP 93–01 and SIOP 2001).
0–2 years 2–4 years 4–10 years 10–18 years Total p-value
N % N % N % N % N %
SIOP stage Stage I 938 65�2 841 43�3 722 35�0 53 28�0 2554 45�4 <0�001
Stage II 272 18�9 471 24�3 479 23�2 49 25�9 1271 22�6
Stage III 163 11�3 332 17�1 416 20�2 38 20�1 949 16�9
Stage IV 66 4�6 295 15�2 447 21�7 49 25�9 857 15�2
Histology Low risk 60 4�2 77 4 161 7�8 17 9 315 5�6 <0�001
Intermediate risk 1261 87�8 1637 84�5 1533 74�3 135 71�8 4566 81�2
High risk: diffuse anaplastic 12 0�8 81 4�2 175 8�5 10 5�3 278 4�9
High risk: blastemal type 105 7�3 142 7�3 193 9�4 26 13�8 466 8�3
Volume at surgery �500 ml 980 83�2 1411 88�4 1462 86�9 97 68�3 3950 85�9 <0�001
>500 ml 198 16�8 185 11�6 221 13�1 45 31�7 649 14�1
https://doi.org/10.1371/journal.pone.0221373.t002
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Fig 2. Martingale residual plots showing excessive risk for EFS (top) and OS (bottom) plotted versus log (age).
The vertical axis in these plots can be interpreted as excess risk (increasing from bottom to top) and the horizontal axis
Prognostic significance of age in patients with Wilms tumour
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We observed that the presence of diffuse anaplasia increases with age, and is a strong
adverse prognostic factor. We could not include molecular markers in the analysis, since copy
number status was only available for a subset of the SIOP 2001 cohort (N = 586), as previously
described.[9] Gain of 1q and loss/LOH of 1p/16q, which are thought to reflect genomic insta-
bility, have been associated with adverse outcome in various reports.[9–15] These and other
copy number changes/LOH appear to be more prevalent in older patients.[11, 12, 15] Three
recent studies that assessed age, 1q gain and 1p/16q loss/LOH in multivariable analysis[9, 13,
14] found 1q gain to be independently associated with relapse and/or survival, while age and
1p/16q loss/LOH did not retain significance (S6 Table). A large study on prognostic molecular
markers (N = 1114) showed that 1p/16q loss/LOH was not independently associated with EFS
when correcting for 1q gain, but suggested prognostic value in the group of patients lacking 1q
gain.[11] Age and 1q gain have not been combined in multivariable models with>1000
patients, but will be prospectively validated in the UMBRELLA SIOP-RTSG protocol.[26, 28,
29] Noteworthy, different biomarkers may be important in patients aged<2 years, particularly
in a nephrectomy-only setting, where 11p15 status was shown to be associated with relapse.[7,
30]
Furthermore, Wilms tumour predisposition syndromes may be a relevant factor to consider
in relation to age at diagnosis and survival, but could not be assessed in this study due to
incomplete data. Wilms tumour predisposition syndromes have been associated with a youn-
ger age at diagnosis and depending on the genetic aberration, a more favorable tumour biol-
ogy. On the other hand, these syndromes carry a higher risk of bilateral/second tumours and
subsequent renal failure. Wilms tumour predisposition was not always evaluated or recognized
in the past, and incompletely registered, as this was beyond the objectives of SIOP 93–01 and
2001. Therefore, we were unable to reliably distinguish between patients with and without a
Wilms tumour predisposition syndrome in the current study. As genomic sequencing
becomes more widely implemented in paediatric oncology, more data will become available to
unravel these associations in the SIOP-RTSG UMBRELLA protocol.[26]
Other limitations of this study included the long period of time during which treatment
evolved based on the results of two successive clinical trials, and missing data requiring impu-
tation. When limiting the analysis to SIOP 2001 only, a more uniform but slightly smaller
cohort, age retained significance in relation to EFS but not OS.
The two most recent COG protocols have provided some insight into the outcomes after
reduced treatment for young patients[5, 7], but this is difficult to compare to SIOP-RTSG pro-
tocols, in which response to pre-operative chemotherapy influences risk stratification.[24] Yet,
since age seems to emerge as an even more important adverse prognostic factor in reduced
therapy settings[3], it seems sensible to remove older patients from minimal treatment strate-
gies. A decision analysis approach, simulating reduced treatment to model the clinical course
in different age categories, could aid the design of future guidelines for treatment stratifica-
tion.[31]
Overall, these results encourage the consideration of age in the design of future SIOP-RTSG
protocols, albeit after validation of 1q gain, other molecular markers and age as independent
prognostic factors in the UMBRELLA SIOP-RTSG protocol.
is age (logarithmic scale). A smoothed curve (LOWESS: locally weighted scatterplot smoothing) is displayed for
assessing the functional form for age. Median age (of the log or ratio) is indicated in the martingale residual plots with
a dotted line. The grey lines in the plots correspond to the 95% bootstrapped confidence interval. The plots suggest that
an increase in age is linearly associated with the risk of an event. No specific change point (knot) can be clearly
observed.
https://doi.org/10.1371/journal.pone.0221373.g002
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Fig 3. Survival of paediatric patients with Wilms tumour according to age. Kaplan Meier curves showing estimated
5-year event-free survival (EFS) (top) and estimated 5-year overall survival (OS) (bottom) per age category, N = 5585.
https://doi.org/10.1371/journal.pone.0221373.g003
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Table 3. Prognostic factors for event-free survival (EFS) in patients with Wilms tumour (N = 4596).
Characteristic Events Univariable Multivariable, age
categorized
Multivariable, age linear
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex Female 361 1 1 1
Male 305 0�98 (0�84–1�14) 0�78 1 (0�86–1�17) 1 0�99 (0�85–
1�15)
0�88
Age at diagnosis, categorized
(years)
0–2 97 1 1
2–4 203 1�56 (1�23–1�99) 0�0003 1�34 (1�05–
1�72)
0�02
4–10 332 2�49 (1�99–3�12) <
0�0001
1�83 (1�44–
2�32)
<
0�0001
10–18 34 3�18 (2�15–4�70) <
0�0001
1�74 (1�15–
2�61)
0�01
Age at diagnosis,
linear (years)
666 1�12 (1�09–1�15) <
0�0001
1�06 (1�03–
1�09)
<
0�0001
Overall stage I 204 1 1 1
II 134 1�30 (1�04–1�61) 0�019 1�13 (0�91–
1�41)
0�28 1�17 (0�94–
1�46)
0�17
III 146 2�07 (1�68–2�56) <
0�0001
1�6 (1�28–2) <
0�0001
1�66 (1�33–
2�07)
<
0�0001
IV 182 3�08 (2�52–3�77) <
0�0001
2�97 (2�4–3�67) <
0�0001
3�13 (2�54–
3�86)
<
0�0001
Histological risk group Intermediate risk 471 1 1 1
High risk: diffuse
Anaplastic
92 14�71 (12�44–
17�38)
<
0�0001
2�9 (2�29–3�68) <
0�0001
3�12 (2�48–
3�94)
<
0�0001
High risk: blastemal type 90 2�48 (1�94–3�17) <
0�0001
2�16 (1�72–
2�72)
<
0�0001
2�13 (1�69–
2�69)
<
0�0001
Low risk 13 0�59 (0�35–1�01) 0�052 0�27 (0�15–
0�46)
<
0�0001
0�28 (0�16–
0�48)
<
0�0001
Biopsy No 463 1 1 1
Yes 203 1�44 (1�22–1�70) <
0�0001
1�1 (0�89–1�37) 0�37 1�06 (0�85–
1�31)
0�61
Volume at surgery �500 ml 502 1 1 1
>500 ml 164 2�24 (1�88–2�68) <
0�0001
2�03 (1�69–
2�44)
<
0�0001
1�93 (1�6–2�32) <
0�0001
Univariable and Multivariable Cox regression models of event-free survival (EFS), stratified by national/regional study group and database (SIOP 93–01 and SIOP
2001), with age categorized and age linear.
https://doi.org/10.1371/journal.pone.0221373.t003
Table 4. Prognostic factors for overall survival (OS) in patients with Wilms tumour (N = 4596).
Characteristic Events Univariable Multivariable, age
categorized
Multivariable, age linear
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Sex Female 168 1 1 1
Male 123 0�84 (0�67–1�06) 0�14 0�85 (0�67–
1�07)
0�16 0�84 (0�66–1�06) 0�13
Age at diagnosis, categorized
(years)
0–2 31 1 1
2–4 83 1�96 (1�30–2�96) 0�0014 1�29 (0�85–
1�97)
0�23
4–10 159 3�63 (2�47–5�33) <
0�0001
1�67 (1�11–
2�51)
0�01
10–18 18 5�16 (2�89–9�23) <
0�0001
1�87 (1�02–
3�44)
0�04
(Continued)
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Supporting information
S1 Fig. Inclusion flowchart of patients with histologically proven Wilms tumour from the
SIOP 93–01 and SIOP 2001 database.
(DOCX)
S1 Table. Previously published literature including age as a variable for outcome in Wilms
tumour (WT).
(DOCX)
S2 Table. Prognostic factors for event-free survival (EFS) in patients with Wilms tumour,
missing volume imputed (N = 5631).
(DOCX)
S3 Table. Prognostic factors for event-free survival (EFS) in patients with Wilms tumour,
SIOP 2001 only (N = 3132).
(DOCX)
S4 Table. Prognostic factors for overall survival (OS) in patients with Wilms tumour, miss-
ing volume imputed (N = 5631).
(DOCX)
Table 4. (Continued)
Characteristic Events Univariable Multivariable, age
categorized
Multivariable, age linear
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age at diagnosis,
linear (years)
291 1�15 (1�11–1�19) <
0�0001
1�04 (1–1�08) 0�06
Overall stage I 56 1 1 1
II 48 1�69 (1�15–2�49) 0�0076 1�43 (0�97–
2�11)
0�07 1�47 (1–2�17) 0�05
III 76 3�91 (2�77–5�52) <
0�0001
2�76 (1�93–
3�94)
<
0�0001
2�86 (2�01–4�09) <
0�0001
IV 111 6�65 (4�82–9�17) <
0�0001
6�78 (4�82–
9�53)
<
0�0001
7�14 (5�09–
10�01)
<
0�0001
Histological risk group Intermediate risk 152 1 1 1
High risk: diffuse
Anaplastic
73 10�13 (7�66–
13�40)
<
0�0001
6�91 (5�09–
9�39)
<
0�0001
7�38 (5�47–9�95) <
0�0001
High risk: blastemal type 57 4�01 (2�96–5�44) <
0�0001
4�55 (3�31–
6�25)
<
0�0001
4�58 (3�33–6�3) <
0�0001
Low risk 9 0�86 (0�44–1�68) 0�65 0�53 (0�27–
1�05)
0�07 0�55 (0�28–1�09) 0�09
Biopsy No 192 1 1 1
Yes 99 1�66 (1�30–2�11) <
0�0001
1�03 (0�75–1�4) 0�87 1�03 (0�75–1�41) 0�85
Volume at surgery �500 ml 201 1 1 1
>500 ml 90 2�99 (2�33–3�83) <
0�0001
2�23 (1�7–2�91) <
0�0001
2�19 (1�67–2�85) <
0�0001
Univariable and Multivariable Cox regression models of overall survival (OS), stratified by national/regional study group and database (SIOP 93–01 and SIOP 2001),
with age categorized and age linear.
https://doi.org/10.1371/journal.pone.0221373.t004
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S5 Table. Prognostic factors for overall survival (OS) in patients with Wilms tumour,
SIOP 2001 only (N = 3132).
(DOCX)
S6 Table. Previously published studies including 1q gain in multivariable analysis.
(DOCX)
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